JPS59176247A - Method for preventing decomposition of water-soluble azunole - Google Patents

Method for preventing decomposition of water-soluble azunole

Info

Publication number
JPS59176247A
JPS59176247A JP5204583A JP5204583A JPS59176247A JP S59176247 A JPS59176247 A JP S59176247A JP 5204583 A JP5204583 A JP 5204583A JP 5204583 A JP5204583 A JP 5204583A JP S59176247 A JPS59176247 A JP S59176247A
Authority
JP
Japan
Prior art keywords
water
soluble
drug
azunole
decomposition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5204583A
Other languages
Japanese (ja)
Inventor
Kazuo Ohira
一夫 大平
Takahito Hasegawa
長谷川 孝人
Fumiko Susaki
洲岬 文子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiyo Pharmaceutical Industry Co Ltd
Original Assignee
Taiyo Pharmaceutical Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiyo Pharmaceutical Industry Co Ltd filed Critical Taiyo Pharmaceutical Industry Co Ltd
Priority to JP5204583A priority Critical patent/JPS59176247A/en
Publication of JPS59176247A publication Critical patent/JPS59176247A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To prevent the decomposition of water-soluble azunole or a drug containing the same, and to keep its drug action for a long period, by sealing the drug together with a disoxidation agent. CONSTITUTION:The decomposition of water-soluble azunole of formula having excellent anti-inflammatory action, histamine-release suppressing action, etc. is prevented, and the activities of the compound are maintained for a long period, by sealing the azunole or a drug containing the same together with a disoxidation agent [e.g. Ageless (commercial name of a product of Mitsubishi Gas Chemical Co.) packed with a gas-permeable material such as paper, cloth or perforated plastic film, etc.]. It is preferable to use a disoxidation agent capable of absorbing 200-1,000ml of oxygen per 1kg of the water-soluble azulene or 500-1,000 tablets of the drug or 500g of the granules of the drug.

Description

【発明の詳細な説明】 本発明は水溶性アズノールの分解を防止し、その薬効を
長期間保持する方法に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for preventing the decomposition of water-soluble aznol and maintaining its medicinal efficacy for a long period of time.

水溶性アズノール〔化学名二1,4−ジメfh−7−イ
7グロビルアズレンー3−スルホン酸ナトリウム〕は次
式(1)、 で表わされる化合物で、優れた消炎作用、ヒスタミン遊
離抑制作用等を有し、現在臨床において広く使用されて
いる。
Water-soluble Azunol [chemical name: sodium 2-1,4-dimefh-7-i7globylazulene-3-sulfonate] is a compound represented by the following formula (1), and has excellent anti-inflammatory and histamine release inhibitory effects. etc., and are currently widely used in clinical practice.

水溶性アズノールは、一般に錠剤、顆粒剤の形で製剤化
しているが、水溶性アズノールは熱に対して不安定であ
り、これを室温で保存すると分解して次式(静 H3 で表わされるグアイアズレン〔化学名:1゜4−ジメチ
ル−7−イングロビルアズレン〕に分解し、薬効が低下
して商品価値が失われる。
Water-soluble Aznol is generally formulated in the form of tablets or granules, but water-soluble Aznol is unstable to heat and decomposes when stored at room temperature. It decomposes into [chemical name: 1゜4-dimethyl-7-inglobil azulene], resulting in decreased medicinal efficacy and loss of commercial value.

そこで、従来、水溶性アズノール及びこれを含有する製
剤は、この分解を防止するために低温(5℃以下)で保
存する方法がとられている。しかし、保存及び流通過程
において薬剤を5℃以下の温度で保存するということは
極めて煩雑かつ困難であり、その有利な保存法が望まれ
ていた。
Therefore, conventionally, water-soluble Azunol and formulations containing the same have been stored at low temperatures (5° C. or lower) to prevent this decomposition. However, it is extremely complicated and difficult to preserve drugs at temperatures below 5° C. during the storage and distribution process, and an advantageous preservation method has been desired.

従来、水溶性アズノールが熱によって分解することは知
られているが、その他の髪因についての研究はなされて
いない。そこで、本発明者は種々の観点からその安定性
について鋭意研究を行った結果、水溶性アズノールは酸
素の存在によって分解されること、従って脱酸素剤と共
に包装すれば室温において分解を防止し、長期間安定に
保持できることを見出し、本発明を完成した。
Although it has been known that water-soluble Azunol is decomposed by heat, no research has been conducted on other causes of hair loss. Therefore, the inventor of the present invention conducted extensive research on its stability from various viewpoints and found that water-soluble Azunol is decomposed in the presence of oxygen.Therefore, if it is packaged with an oxygen scavenger, it will prevent decomposition at room temperature and will last for a long time. The present invention was completed by discovering that it can be stably maintained for a long period of time.

すなわち、本発明は、水溶性アズノール又はこれを含有
する製剤を脱酸素剤と共に密封包装することを特徴とす
る水溶性アズノールの分解防止方法を提供するものであ
る。
That is, the present invention provides a method for preventing the decomposition of water-soluble Azunol, which comprises sealing and packaging water-soluble Azunol or a preparation containing the same together with an oxygen absorber.

本発明方法において、脱酸素剤は紙、布あ乙 るいは細孔を有するプラスチック等の通気性材料で包装
したものが使用され、これは例えばエージレス(三菱ガ
ス化学社製商品名)、バイタロン(東亜合成化学社製商
品名)、セキュール(日本曹達社製商品名)等として市
販されている。
In the method of the present invention, the oxygen scavenger used is one packaged with a breathable material such as paper, cloth, or plastic with pores. It is commercially available as (trade name manufactured by Toagosei Kagaku Co., Ltd.), Secur (trade name manufactured by Nippon Soda Co., Ltd.), etc.

1 本発明方法を実施するには、上記脱酸素剤を水溶性
アズノール又はその製剤と混和しないようにし7て、そ
の包装容器中に密封する。
1. To carry out the method of the invention, the oxygen scavenger is made immiscible with the water-soluble Aznol or its formulation and sealed in its packaging container.

例えば包装された脱酸素剤を水溶性アズノール又はその
製剤と共に非通気性容器、例えばビン又はアルミ、バリ
アロン、ボブロン袋等に入わで密封すればよい。
For example, the packaged oxygen scavenger may be sealed together with water-soluble Azunol or its preparation in a non-breathable container, such as a bottle or an aluminum, Variron, or Boblon bag.

脱酸素剤の量は製剤の形態によっても異なるが、通常水
溶性アズレン原末i、Ky、@剤500〜1000錠、
顆粒500fに対し約200〜1000mの酸素吸収量
を有する脱酸素剤を使用するのが好ましい。
The amount of oxygen scavenger varies depending on the form of the preparation, but usually water-soluble azulene bulk powder I, Ky, @ agent 500 to 1000 tablets,
Preferably, an oxygen scavenger is used which has an oxygen absorption capacity of about 200 to 1000 m per 500 f of granules.

このようにするときは、極めて簡単な操作で、後述の実
施例に示す如く、水溶性アズノールを室温においても長
期間分解されず安定に保持することができる。
In this case, the water-soluble azunol can be stably maintained without being decomposed for a long period of time even at room temperature, as shown in the Examples below, with extremely simple operations.

次に実施例を挙けて説明する。Next, an example will be given and explained.

実施例1 水溶性アズノール500f及び[エージレスZ−100
041個(酸素吸収量10100O)を0.81容のフ
タ付きガラスビンに入れ、各温度で保存してその残存率
を調べた。また、水溶性アズノール500fのみをO,
S を容のフタ利きガラスビンに入れたものを対照とし
た。
Example 1 Water-soluble Azunol 500f and [Ageless Z-100
041 pieces (oxygen absorption amount: 10,100 O) were placed in a 0.81-volume glass bottle with a lid, stored at various temperatures, and the residual rate was examined. In addition, only water-soluble Azunol 500f was added to O,
As a control, S was placed in a glass bottle with a lid.

尚水溶性アズノールの残存率は次の方法によって測定し
た。すなわち、検体的0.1fに水60−を加え、約2
0分間振盪し、水を加えて正確に100−とする。この
溶液1〇−を取り水を加えて50mとし試料溶液とし、
油長10mm、波長570 nmにて吸光度(A)を測
定し含有率を求め、初期含有率を100とし残存率を求
める。
The residual rate of water-soluble Azunol was measured by the following method. That is, adding 60 - of water to the sample 0.1f, approximately 2
Shake for 0 minutes and add water to make exactly 100-. Take this solution 10- and add water to make it 50m, use it as a sample solution,
The absorbance (A) is measured at an oil length of 10 mm and a wavelength of 570 nm to determine the content, and the initial content is set to 100 to determine the residual rate.

測定時含有率 その結果は第1− Tlj表(本発明品)及び第1−(
2)表(対照)に示すとおりである。
The content rate during measurement and the results are shown in Table 1-Tlj (product of the present invention) and Table 1-(
2) As shown in the table (control).

第1−(1)表 本発明品 以下余白 第1−(2)表 対照 実施例2 (1)錠剤 水溶性アズノール    2(■) 乳  糖              42結晶セルロ
ース     40 コーンスターチ     12 炭酸水素ナトリウム   0.5 アラビアゴム      3 ステアリン&カルシウム    0.5以上の組成から
常法によって錠剤1個を作った。
Table 1-(1) Table 1-(2) Margins below the present invention Comparative Example 2 (1) Tablet water-soluble Azunol 2 (■) Lactose 42 Crystalline cellulose 40 Corn starch 12 Sodium hydrogen carbonate 0.5 Gum arabic 3 Stearin & Calcium One tablet was made by a conventional method from a composition of 0.5 or more.

(11)上記錠剤1,000個及び「バイタロ7 LH
−1000J 1 (mを0.5を容のフタ付きガラス
ビンに入れ、30℃で6ケ月間保存したが、水溶性アズ
ノールの分解は認められなかった。
(11) 1,000 tablets and “Vitalo 7 LH”
-1000J 1 (0.5 m) was placed in a glass bottle with a lid and stored at 30°C for 6 months, but no decomposition of water-soluble azunol was observed.

実施例3 (1)顆粒 水溶性アズノール    10(■) 乳  糖             784.9マンニ
トール      200 炭酸水素ナトリウム  5 t−メントーkO11 以上の組成から常法によって顆粒1yを作つた。
Example 3 (1) Granules Water-soluble Azunol 10 (■) Lactose 784.9 Mannitol 200 Sodium bicarbonate 5 T-menthol kO11 Granules 1y were prepared from the above composition by a conventional method.

(11)上記顆粒500f及び「セキュール人−100
0J1個をO,St容のアルミ袋に入れて密封し、30
℃で6ケ月間保存したが、水溶性アズノールの分解は認
められなかった。
(11) The above granules 500f and “Sekurujin-100”
Put 1 piece of 0J into an aluminum bag of O, St capacity, seal it, and add 30
Although it was stored at ℃ for 6 months, no decomposition of water-soluble azunol was observed.

以上 出願人 大洋薬品工業株式会社that's all Applicant Taiyo Pharmaceutical Co., Ltd.

Claims (1)

【特許請求の範囲】[Claims] 1、 水溶性アズノール又はこれを含有する製剤を脱酸
素剤と共に密封包装することを特徴とする水溶性アズノ
ールの分解防止方法。
1. A method for preventing the decomposition of water-soluble Azunol, which comprises sealingly packaging water-soluble Azunol or a preparation containing the same together with an oxygen absorber.
JP5204583A 1983-03-28 1983-03-28 Method for preventing decomposition of water-soluble azunole Pending JPS59176247A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5204583A JPS59176247A (en) 1983-03-28 1983-03-28 Method for preventing decomposition of water-soluble azunole

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5204583A JPS59176247A (en) 1983-03-28 1983-03-28 Method for preventing decomposition of water-soluble azunole

Publications (1)

Publication Number Publication Date
JPS59176247A true JPS59176247A (en) 1984-10-05

Family

ID=12903843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5204583A Pending JPS59176247A (en) 1983-03-28 1983-03-28 Method for preventing decomposition of water-soluble azunole

Country Status (1)

Country Link
JP (1) JPS59176247A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1241110A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs
EP1243524A3 (en) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
JP2010116337A (en) * 2008-11-12 2010-05-27 Kotobuki Seiyaku Kk Stable solid preparation of egualen sodium
WO2013057724A1 (en) 2011-10-21 2013-04-25 Ranbaxy Laboratories Limited Packaging for alitretinoin

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1241110A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs
EP1243524A3 (en) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
JP2010116337A (en) * 2008-11-12 2010-05-27 Kotobuki Seiyaku Kk Stable solid preparation of egualen sodium
WO2013057724A1 (en) 2011-10-21 2013-04-25 Ranbaxy Laboratories Limited Packaging for alitretinoin

Similar Documents

Publication Publication Date Title
JPH06508839A (en) Reactive injection foaming system
US20060003057A1 (en) Gas-release packet with frangible sub-packet
JPH0420657B2 (en)
JPH025726B2 (en)
JPH01172319A (en) Effervescent bathing agent composition
WO2019171639A1 (en) Cartridge, hydrogen gas inhaler, and hydrogen-gas-generating mixture
JPH04207194A (en) Stabilized transglutaminase composition and method for preserving the same
US3016336A (en) Deoxygenating method and product
JPS59176247A (en) Method for preventing decomposition of water-soluble azunole
TW200306781A (en) Delivery systems for cyclopropene compounds
JPH10182687A (en) Stabilization of storage of acarbose
EP3377182B1 (en) Storage-stable solid peroxymonosulfate composition
JPS62252723A (en) Production of nicorandil tablet
US9481652B2 (en) Packaged product of solid preparation containing 5-hydroxy-1H-imidazole-4-carboxamide or salt thereof, or hydrate thereof
JPS5930879A (en) Frothing molded product
JP5708141B2 (en) Formulation for oral administration for preparing solution for oral administration
JPS58177137A (en) Carbon dioxide gas absorbent
US20040081727A1 (en) Gas-release packet with frangible sub-packet
JPS63270624A (en) Production of stabilized nicorandil pharmaceutical
JPH07106295B2 (en) Humidifier
JPS5829069B2 (en) Freshness preserving agent
JPS6041986B2 (en) oxygen absorber
JPH0130530B2 (en)
JPH0157947B2 (en)
JPH1015032A (en) Stabilized 5-aminosalycilic acid solid pharmaceutical